

Blue Medicare Advantage expands specialty pharmacy precertification list

Effective for dates of service on and after **December 1, 2022**, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.

Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

HCPCS or CPT® codes	Medicare Part B drugs
C9399, J3490, J3590, J9999	Opdualag (nivolumab and relatlimab-rmbw)
C9096	Releuko (filgrastim-ayow)
A9699	Pluvicto (lutetium lu 177 vipivotide tetraxetan)